U.S. Patent and Trademark Office confirms validity of patent for UCB's Vimpat®

- **IPR proceedings in favor of UCB**

Brussels (Belgium), 22 March 2017 – UCB announces today that the U.S. Patent and Trademark Office (USPTO) confirmed the validity of U.S. patent RE38,551 related to Vimpat® (*lacosamide*), UCB's anti-epileptic drug, in the Inter Partes Review (IPR) proceedings.

In May 2016, the U.S. Patent and Trademark Office had agreed to initiate IPR proceedings, following Argentum Pharmaceuticals LLC's Petition, to review whether the U.S. patent RE38,551 patent is invalid due to obviousness.

"We are pleased with the outcome of the IPR review," said Anna S. Richo, Executive Vice President & General Counsel at UCB. "In finding that the Petitioner failed to establish that any of the claims of the patent are unpatentable for obviousness, the USPTO's decision further confirms, as did the Delaware District Court decision in August 2016, the strength of our intellectual property for Vimpat®."

This decision supports UCB's commitment to epilepsy patients.

In August 2016, the U.S. Delaware District Court confirmed the validity of U.S. patent RE38,551 related to Vimpat® (lacosamide).

For further information

Corporate Communications	**Investor Relations**
France Nivelle, Global Communications, UCB T +32.2.559.9178, france.nivelle@ucb.com	Antje Witte, Investor Relations, UCB T +32.2.559.94.14, antje.witte@ucb.com
Laurent Schots, Media Relations, UCB T+32.2.559.92.64, laurent.schots@ucb.com	Isabelle Ghellynck, Investor Relations UCB T +32 2 559 9588, isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 700 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

About Vimpat

Lacosamide (tradename Vimpat®) is approved as adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy (ages ≥ 17 years in the U.S., ages ≥ 16 years in the EU) and in the U.S. also as monotherapy. In the EU, Lacosamide is not currently approved for use as monotherapy.

Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this document and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.